Letters

Adverse events associated with mefloquine

BMJ 1996; 313 doi: https://doi.org/10.1136/bmj.313.7071.1552b (Published 14 December 1996) Cite this as: BMJ 1996;313:1552

Study in returned travellers confirms authors' findings

  1. E L Corbett,
  2. J F Doherty,
  3. R H Behrens
  1. Registrar in tropical medicine Senior registrar in tropical medicine Consultant physician in travel medicine Hospital for Tropical Diseases, London NW1 0PE

    EDITOR,—The excess of disabling neuropsychiatric side effects of mefloquine reported by P J Barrett and colleagues has attracted attention.1 Focus on disabling reactions has detracted from milder disturbances, which may be sufficiently common to reduce compliance and increase the risk of malaria.2 We conducted a questionnaire based survey among recently returned travellers to assess the impact of adverse reactions on compliance.

    Altogether 347 questionnaires were returned (response rate 60.5%), 255 of which were from respondents who had been born in malaria free areas, were …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe